NCT07932054 Immune Reconstitution Characteristics and Influencing Factors Following Umbilical Cord Blood Transplantation
| NCT ID | NCT07932054 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Condition | Transplant-Related Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 280 participants |
| Start Date | 2026-10-16 |
| Primary Completion | 2028-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 280 participants in total. It began in 2026-10-16 with a primary completion date of 2028-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study collects immune reconstitution data of umbilical cord blood transplant recipients at multiple time points after transplantation to explore the characteristics and relevant influencing factors of immune reconstitution.
Eligibility Criteria
Inclusion Criteria: 1. umbilical cord blood transplant; 2. Patients have to sign an informed consent form before the start of the research procedure. Exclusion Criteria: Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.
Frequently Asked Questions
Who can join the NCT07932054 clinical trial?
This trial is open to participants of all sexes, studying Transplant-Related Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07932054 currently recruiting?
Yes, NCT07932054 is actively recruiting participants. Visit ClinicalTrials.gov or contact Institute of Hematology & Blood Diseases Hospital, China to inquire about joining.
Where is the NCT07932054 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT07932054 clinical trial?
NCT07932054 is sponsored by Institute of Hematology & Blood Diseases Hospital, China. The trial plans to enroll 280 participants.